Cytokinetics Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cytokinetics stock.
View analyst ratings for Cytokinetics or view top-rated stocks.

Wall Street analysts have given Cytokinetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cytokinetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Cytokinetics.

Cytokinetics, Incorporated (NASDAQ:CYTK) released its quarterly earnings data on Thursday, February, 25th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.14. Cytokinetics had a negative net margin of 209.88% and a negative trailing twelve-month return on equity of 3,065.14%.
View Cytokinetics' earnings history.

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 63.6% and is now trading at $19.68.
View which stocks have been most impacted by COVID-19.

Cytokinetics updated its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $23-28 million, compared to the consensus revenue estimate of $31.36 million.

10 analysts have issued 1-year price objectives for Cytokinetics' stock. Their forecasts range from $16.00 to $48.00. On average, they expect Cytokinetics' stock price to reach $32.00 in the next year. This suggests a possible upside of 62.6% from the stock's current price.
View analysts' price targets for Cytokinetics or view top-rated stocks among Wall Street analysts.

16 employees have rated Cytokinetics CEO Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among Cytokinetics' employees.

Some companies that are related to Cytokinetics include Blueprint Medicines (BPMC), Galapagos (GLPG), Perrigo (PRGO), Turning Point Therapeutics (TPTX), Biohaven Pharmaceutical (BHVN), Atea Pharmaceuticals (AVIR), Emergent BioSolutions (EBS), Schrödinger (SDGR), Sage Therapeutics (SAGE), Arena Pharmaceuticals (ARNA), Hutchison China MediTech (HCM), Reata Pharmaceuticals (RETA), PTC Therapeutics (PTCT), Nektar Therapeutics (NKTR) and ChemoCentryx (CCXI).
View all of CYTK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.40%), PFM Health Sciences LP (1.37%), Northern Trust Corp (1.18%), Bank of New York Mellon Corp (0.97%), Opaleye Management Inc. (0.82%) and Peregrine Capital Management LLC (0.79%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Ching Jaw, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, JPMorgan Chase & Co., Nuveen Asset Management LLC, ClariVest Asset Management LLC, Northern Trust Corp, Russell Investments Group Ltd., Pinnacle Associates Ltd., and Bank of New York Mellon Corp. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Ching Jaw, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, and Wendall Wierenga.
View insider buying and selling activity for Cytokinetics or view top insider-selling stocks.

CYTK stock was bought by a variety of institutional investors in the last quarter, including PFM Health Sciences LP, BlackRock Inc., Peregrine Capital Management LLC, Artal Group S.A., Opaleye Management Inc., CM Management LLC, Candriam Luxembourg S.C.A., and Hillhouse Capital Advisors LTD.. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics or or view top insider-buying stocks.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYTK stock can currently be purchased for approximately $19.68.

Cytokinetics has a market capitalization of $1.40 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.

Cytokinetics employs 156 workers across the globe.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics is headquartered at 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]